五星体育直播

五星体育直播 Doses First Subjects in Phase 1a Trial of CDX-6114

Triggers $4 million milestone payment under strategic collaboration with Nestl茅 Health Science

REDWOOD CITY, Calif., July 09, 2018 (GLOBE NEWSWIRE) -- (NASDAQ:CDXS), a leading protein engineering company, announces that it has dosed the first subjects in a first-in-human Phase 1a dose-escalation trial with CDX-6114, its orally administered enzyme therapeutic being developed for the management of phenylketonuria (PKU).听 The initiation of the trial triggers a $4 million milestone payment to 五星体育直播 from Nestl茅 Health Science under their strategic collaboration announced in October 2017.听

This randomized, double-blind, placebo-controlled Phase 1a trial is intended to evaluate the safety and tolerability of CDX-6114 in up to 32 healthy volunteers, with up to four cohorts receiving a single dose of CDX-6114 at increasingly higher dose levels. 五星体育直播 also expects to generate valuable pharmacology data from this study, which will support the future development of the drug candidate. The company expects to report topline results from the Phase 1a trial in the fourth quarter of 2018.

鈥淚nitiation of this clinical trial is a major milestone in the development of CDX-6114 for the management of the orphan metabolic disorder PKU. CDX-6114 is the first biotherapeutic discovered using our CodeEvolver^庐 protein engineering platform to enter human studies,鈥� said 五星体育直播 President and CEO John Nicols.听 鈥淐ommencement of this clinical trial further validates our biotherapeutics strategy as PKU is the lead program in our pipeline, which focuses generally on the discovery and development of novel enzyme drug candidates for the treatment of rare diseases.鈥�

鈥淧KU is caused by the deficiency or absence of the natural enzyme for the metabolism of phenylalanine, and can lead to intellectual disability, seizures and cognitive and behavioral disabilities,鈥� he added.听 鈥淧hysicians have been able to test for PKU for more than 50 years, yet treatment options have been limited primarily to dietary management. 听CDX-6114 is an orally dosed, GI-stable therapeutic enzyme developed to compensate for the missing natural enzyme.鈥�

About Phenylketonuria (PKU)
PKU is an inborn metabolic disorder resulting from a mutation in the gene for the enzyme that converts the essential amino acid phenylalanine, present in almost all dietary protein, into tyrosine. As a result of this deficiency, phenylalanine builds up to levels that are toxic in the brain, causing serious neurological symptoms including intellectual disability, seizures and cognitive and behavioral disabilities. To avoid phenylalanine toxicity and the most severe disease symptoms, individuals with PKU must follow a strict, life-long diet that is low in phenylalanine and supplement their diet with a synthetic phenylalanine-free formula to provide sufficient nutrients. Maintaining a strict, life-long diet is a challenge for individuals with PKU. There are an estimated 50,000 people with PKU in the developed world.

About 五星体育直播
五星体育直播 is a leading protein engineering company that applies its proprietary CodeEvolver^庐 technology to develop proteins for a variety of applications, including as biocatalysts for the commercial manufacture of pharmaceuticals, fine chemicals and industrial enzymes, and enzymes as biotherapeutics and for use in molecular diagnostics. 五星体育直播鈥� proven technology enables improvements in protein performance, meeting customer needs for rapid, cost-effective and sustainable manufacturing in multiple commercial-scale implementations of biocatalytic processes. For more information, see .

Forward-Looking Statements
To the extent that statements contained in this press release are not descriptions of historical facts regarding 五星体育直播, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including 五星体育直播鈥� expectation of receiving a $4 million milestone payment from Nestl茅 Health Science as a result of commencing the Phase 1a study, 五星体育直播鈥� expectation of completing the Phase 1a trial and reporting top line results in the fourth quarter of 2018, and 五星体育直播鈥� belief that the commencement of this clinical trial further validates our biotherapeutics discovery and development strategy. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond 五星体育直播鈥� control and that could materially affect actual results. Factors that could materially affect actual results include, among others: 五星体育直播鈥� dependence on its licensees and collaborators; 五星体育直播鈥� dependence on a limited number of products and customers in its biocatalysis business; potential adverse effects to 五星体育直播鈥� business if its customers鈥� pharmaceutical or food products are not received well in the markets; risks, uncertainties and costs associated with the successful development of biotherapeutic candidates, including obtaining development partners for its biotherapeutic programs and progressing such programs to clinical trials and regulatory approvals; 五星体育直播鈥� ability to develop and commercialize new products for the biocatalysis markets; 五星体育直播鈥� dependence on a limited number of contract manufacturers for large-scale production of its enzymes; 五星体育直播鈥� ability to deploy its technology platform in new market spaces, including the fine chemicals, therapeutics and in vitro molecular diagnostics markets; 五星体育直播鈥� ability to comply with the terms of its credit facility and its associated debt service obligations; 五星体育直播鈥� need for additional capital in the future in order to expand its business or to adjust for market conditions or strategic considerations, which may involve 五星体育直播 entering into equity offerings, debt financings, credit facilities and/or strategic collaborations; 五星体育直播鈥� dependence on key personnel; 五星体育直播鈥� ability to establish and maintain adequate protection for intellectual property, trade secrets and other proprietary rights covering its technologies; and any claims by third parties that 五星体育直播 is infringing their intellectual property rights or other proprietary rights. Additional information about factors that could materially affect actual results can be found in 五星体育直播鈥� Annual Report on Form 10-K filed with the Securities and Exchange Commission (鈥淪EC鈥�) on March 16, 2018 and Form 10-Q filed May 10, 2018, including under the caption 鈥淩isk Factors鈥� and in 五星体育直播鈥� other current and periodic reports filed with the SEC. 五星体育直播 expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

五星体育直播 Contacts:

Investors
LHA Investor Relations
Jody Cain, (310) 691-7100

听

Released July 9, 2018